United States, White House team, Boosters start September
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
(FDA depending)
Eight months after Pfizer or Moderna
Same brand
News on second dose of J and J in the next few weeks
Mr. Greg Abbott in Texas
Tested positive for COVID-19 on Tuesday
Is in good health and experiencing no symptoms
Mr. Abbott was vaccinated in December
All close contacts being notified
May not always have been wearing a mask recently
Seven million who are immunocompromised
Booster roll out started in Detroit yesterday
Children
Cases, + 121,427 in past 7 days
Hospital admissions, x 3 in past 7 days
Predictive indicators seem to have changed
Data from Israel Health Ministry
[ Ссылка ]
N = 2.5 million (16 and over)
Second dose administered within the 21 to 28 day interval set by national guidelines
A significant drop in protection against hospitalization among people age 65 and older
Who were vaccinated in January and February
Delta (B.1.617.2) variant became the dominant strain in Israel in June 2021
Israel is currently experiencing a new surge of cases
The correlation between antibody dynamics and clinical protection remains undefined
Correlation between time-from-vaccine and incidence of breakthrough infection
We found that the risk for infection was significantly higher for early vaccinees compared to those vaccinated later
Model 1
We matched 329,177 persons in each group
1,911 cases of breakthrough infection were recorded
1,151 of them in the Early Vaccinees group
760 in the Late Vaccinees group
We found a statistically significant 53% increased risk for breakthrough infection in early vaccines (P less than 0.001)
We found a similar trend across all age groups
Model 2
Individuals who were vaccinated in January 2021
Had a 2.26-fold increased risk for breakthrough infection
Compared to individuals who were vaccinated in April 2021
Israel has already started beginning giving booster shots to people older than 50.
Data on all symptomatic sequenced cases of Covid-19 in England
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
[ Ссылка ]
After one dose of Pfizer or AZ, delta efficacy = 31%
After one dose of Pfizer or AZ, alpha efficacy = 49%
After two dose of Pfizer, alpha efficacy = 94%
After two dose of Pfizer, delta efficacy = 88%
After two dose of AZ, alpha efficacy = 75%
After two dose of AZ, delta efficacy = 67%
Data from Qatar
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar
[ Ссылка ]
Effectiveness against any severe, critical, or fatal COVID-19 disease due to delta was 89.7%
Both BNT162b2 (Pfizer) and mRNA-1273 (Moderna) are highly effective in preventing Delta hospitalization and death, but less so in preventing infection
(Moderna may protect against symptomatic infection more than Pfizer)
Paul A. Offit, pediatrician and vaccine expert at Children’s Hospital of Philadelphia
[ Ссылка ]
We could have done a much better job at setting realistic expectations for this vaccine
And I think that’s hurt us.
Because I think people get disappointed.
They think the vaccine isn’t working.”
Centers for Disease Control and Prevention (Leaked PP)
[ Ссылка ]
[ Ссылка ]
July 29, 35,000 breakthrough infections a week
CDC Director Rochelle Walensky
Statement that 97 % of people hospitalized by the virus are unvaccinated
Data was out of date
CDC said Friday
40 to 44% of patients hospitalized with breakthrough infections have compromised immune systems
Heather Scobie, member of the CDC’s Covid-19 Response Team
Delta has high prevalence in the U.S. and has moderate impact on vaccine effectiveness.
The vaccines are likely to still provide protection against severe disease
the potential for waning immunity
Canada, Qatar, Israel, England, Scotland
Vaccine effectiveness at preventing infection ranged 40% to 80%
Effectiveness against severe illness, 90% percent for vaccine recipients overall
(Differences in methodology)
Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security
Breakthrough infections were expected
The goal of the vaccines was to make breakthrough infections clinically inconsequential and that’s what they’re doing
